United Therapeutics acquires Thymmune Therapeutics for USD 140 million upfront

United Therapeutics Corporation

UTHR

0.00

United Therapeutics acquired privately held Thymmune Therapeutics for USD 140 million in cash, subject to post-closing adjustments.
Deal includes potential earn-out payments of up to USD 160 million tied to clinical and regulatory milestones through 2031.
Thymmune develops regenerative thymic cell therapies derived from iPSCs for immune restoration, with applications in transplant tolerance and immune-mediated diseases.
Lead program THY-100 is in preclinical development for congenital athymia, targeting restoration of T-cell function via in vivo neo-thymus formation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202607020630BIZWIRE_USPR_____20260702_BW920280) on July 02, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.